{"transactions":[{"id":1212497,"issuer":{"id":7935,"kind":"organization","name":"Senti Biosciences Holdings, Inc."},"owners":[{"id":82127,"kind":"person","name":"Cross John Harry III","position":1,"cik":"0001806763","reported_name":"Cross John Harry III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-11T20:14:50.000Z","date":"2025-03-07","kind":"grant","planned":false,"acquired":true,"shares":174200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vest on March 3, 2026 and the remainder vest in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":174200,"derivative":{"exercise_price":3.52,"expiration_date":"2035-03-06","underlying":"Common Stock","underlying_shares":174200},"source":{"system":"sec-edgar","filing":"0001854270-25-000026","document":"wk-form4_1741724083.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854270/000185427025000026/wk-form4_1741724083.xml","form_type":"4"}},{"id":1342026,"issuer":{"id":72220,"kind":"organization","name":"Sonnet BioTherapeutics Holdings, Inc.","symbol":"SONN"},"owners":[{"id":82127,"kind":"person","name":"Cross John Harry III","position":1,"cik":"0001806763","reported_name":"Cross John Harry III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-06T02:55:05.000Z","date":"2023-12-11","kind":"grant","planned":false,"acquired":false,"shares":1452,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 11, 2023, the Reporting Person was granted 1,452 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes unvested restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"All amounts reflect the Issuer's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024."}],"balance_after":1588,"source":{"system":"sec-edgar","filing":"0001493152-24-048950","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106838/000149315224048950/ownership.xml","form_type":"4"}},{"id":2008910,"issuer":{"id":72220,"kind":"organization","name":"Sonnet BioTherapeutics Holdings, Inc.","symbol":"SONN"},"owners":[{"id":82127,"kind":"person","name":"Cross John Harry III","position":1,"cik":"0001806763","reported_name":"Cross John Harry III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-17T21:45:39.000Z","date":"2023-02-06","kind":"tax_withholding","acquired":false,"shares":1960,"price":1.06,"value":2077.6,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":23927,"source":{"system":"sec-edgar","filing":"0001493152-23-005464","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106838/000149315223005464/ownership.xml","form_type":"4"}},{"id":2078024,"issuer":{"id":72220,"kind":"organization","name":"Sonnet BioTherapeutics Holdings, Inc.","symbol":"SONN"},"owners":[{"id":82127,"kind":"person","name":"Cross John Harry III","position":1,"cik":"0001806763","reported_name":"Cross John Harry III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-22T21:31:00.000Z","date":"2022-12-14","kind":"grant","acquired":true,"shares":15519,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 14, 2022, the Reporting Person was granted 15,519 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 14, 2022, the Reporting Person was granted 15,519 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes unvested RSUs."}],"balance_after":160684,"source":{"system":"sec-edgar","filing":"0001493152-22-036315","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106838/000149315222036315/ownership.xml","form_type":"4"}},{"id":2300664,"issuer":{"id":72220,"kind":"organization","name":"Sonnet BioTherapeutics Holdings, Inc.","symbol":"SONN"},"owners":[{"id":82127,"kind":"person","name":"Cross John Harry III","position":1,"cik":"0001806763","reported_name":"Cross John Harry III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-04-08T20:30:38.000Z","date":"2021-12-15","kind":"grant","acquired":true,"shares":66951,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 15, 2021, the Reporting Person was granted 66,951 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 15, 2021, the Reporting Person was granted 66,951 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes unvested RSUs."}],"balance_after":145165,"source":{"system":"sec-edgar","filing":"0001493152-22-009485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106838/000149315222009485/ownership.xml","form_type":"4"}},{"id":3093002,"issuer":{"id":72220,"kind":"organization","name":"Sonnet BioTherapeutics Holdings, Inc.","symbol":"SONN"},"owners":[{"id":82127,"kind":"person","name":"Cross John Harry III","position":1,"cik":"0001806763","reported_name":"Cross John Harry III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-07-02T22:17:22.000Z","date":"2020-07-02","kind":"grant","acquired":true,"shares":78214,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 2, 2020, the Reporting Person was granted 78,214 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock\nunits vest as to 50% of the restricted stock units on April 2, 2021 and 50% of the restricted stock units on April 2, 2022."}],"balance_after":78214,"source":{"system":"sec-edgar","filing":"0001493152-20-012570","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1106838/000149315220012570/ownership.xml","form_type":"4"}}]}